HIV Infections Clinical Trial
— PediacamNEGOfficial title:
Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological Mechanisms
The objective of the study is to identify the pathophysiological mechanisms responsible for the induction and maintenance of negative serologies by EIA tests in HIV-infected children treated early with HAART in the ANRS 12225-Pediacam III cohort in Cameroon The hypothesis of better control of HIV infection through interactions between immunological, viral, and genetic factors was made to build the following objectives: - Immunological aspect: lack of humoral response or immune activation - Virological aspect: Reduced HIV reservoir size - Determine the HLA phenotype in the different groups of children included and the KIR genotypes.
Status | Recruiting |
Enrollment | 451 |
Est. completion date | August 30, 2025 |
Est. primary completion date | August 30, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: Case control study - Children included and followed in the ANRS 12225 study - Pediacam III - Having plasma samples in the bio bank during the above-mentioned periods Case:children with at least one negative HIV serology made by ELISA, permanent or transientduring follow-up. Control (4 groups) - HIV-infected children with positive serology and viral load (VL) <400 copies /ml - HIV-infected children with positive serology and VL =400 copies / ml - HIV-uninfected children born to HIV-positive mothers - HIV-uninfected children born to HIV-uninfected mothers Selection of cases and controls will be matched on gestational age (premature <37, term =37 weeks) and year of birth (2007-2008 and 2009-2010). Cross sectional study Inclusion criteria - All children still followed in the ANRS - Pediacam III cohort - Written consent of one of the parents or the guardian and assent of the child if aged = 11 years and complete disclosure of HIV statusfor infected children for participation to the study. Exclusion Criteria: - Refusal by one of the parents or the guardian for the child's participation in the study - No assent of the child (if aged = 11 years and with complete disclosure of HIV status, for infected children) |
Country | Name | City | State |
---|---|---|---|
Cameroon | Hôpital de Jour - Hôpital Laquintinie de Douala | Douala | |
Cameroon | Unité Pédiatrique de Jour - Centre Mère et Enfant de la Fondation Chantal Biya | Yaounde | |
Cameroon | Service de Pédiatrie - Centre Hospitalier d'Essos | Yaoundé |
Lead Sponsor | Collaborator |
---|---|
ANRS, Emerging Infectious Diseases | Centre Hospitalier D'essos, Centre Hospitalier Universitaire d'Orléans, Centre Mère et Enfant de la Fondation Chantal Biya, Centre Pasteur du Cameroun, Hopital Universitaire Robert-Debre, Hospital General De Douala, Institut Pasteur, Université Paris-Sud |
Cameroon,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Level of pro-inflammatory and anti-inflammatory cytokines, chimiokines in the plasma | Measure of sCD14 (µg/ml). Levels of these biomarkers will be compared across all groups. | 18 months | |
Primary | Level of pro-inflammatory and anti-inflammatory cytokines, chimiokines in the plasma | Measure of BAFF using luminex or commercially available ELISA quantification kits. Levels of these biomarkers will be compared across all groups. | 18 months | |
Primary | Level of pro-inflammatory and anti-inflammatory cytokines, chimiokines in the plasma | Measure of CXCL13 using luminex or commercially available ELISA quantification kits. Levels of these biomarkers will be compared across all groups. | 18 months | |
Primary | Level of pro-inflammatory and anti-inflammatory cytokines, chimiokines in the plasma | Measure of TNF-a (pg/ml). Levels of these biomarkers will be compared across all groups. | 18 months | |
Primary | Level of pro-inflammatory and anti-inflammatory cytokines, chimiokines in the plasma | Measure of IL-10 (pg/ml). Levels of these biomarkers will be compared across all groups. | 18 months | |
Primary | Level of pro-inflammatory and anti-inflammatory cytokines, chimiokines in the plasma | Measure of IP-10 (pg/ml). Levels of these biomarkers will be compared across all groups. | 18 months | |
Primary | Level of pro-inflammatory and anti-inflammatory cytokines, chimiokines in the plasma | Measure of TRAIL (ng/ml). Levels of these biomarkers will be compared across all groups | 18 months | |
Secondary | - Humoral response to vaccines against tetanus, pertussis, and viral hepatitis B | Serum concentrations of human IgG antibodies against tetanus-toxoid, pertussis, and viral hepatitis B will be measured using commercially available ELISA quantification kits and results will be given as IU/mL | 18 months | |
Secondary | - Functional and phenotypic characterization of B and T lymphocytes | Level (cells/µL or percentage) of T and B-cell lymphocytes subpopulations will be assess in blood using flow cytometry. Functional characterization of T and B lymphocytes will be done by cell culture following by cytokine production titration | 18 months | |
Secondary | - Size of the HIV reservoir | Measure total (copies/million PBMC), integrated (copies/million PBMC), unintegrated (copies/million PBMC) HIV DNA level in Peripheral Blood Mononuclear Cells (PBMC) | 18 months | |
Secondary | - Residual viremia in perinatally HIV-infected adolescent | Any detectable HIV-RNA below 50 copies/mL | 18 months | |
Secondary | - Level of HIV plasma p24 | Measure plasma level of HIV p24 antigen (fg/ml) using ultrasentsitive technique called Simoa (Single molecule array) | 18 months | |
Secondary | - HLA phenotype and the KIR genotypes | HLA-B (27 et 57), HLA-B35 ou 53, HLA-C16:01+KIR2DL3+ | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |